Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 78

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 6
Chunk 78
---
arm Limited (ASX:NOX) (appointed in March 2016), Iris Metals Limited (ASX:IR1) (appointed in December 2020) and EverGreen Lithium Limited (ASX:EG1) (appointed in January 2022). Mr. Marks has a MBA, Bachelor of Economics, Bachelor of Law, and Grad Dip in Commercial Law Experience and expertise.

Mr. Brian Meltzer has served as a director of our Group since December 1999. Subsequent to several years as Chief Economist of ICI Australia (now Orica), Mr. Meltzer spent 25 years in investment banking. His breadth of expertise includes major property transactions, corporate advisory, corporate finance, management buyouts, venture capital and large-scale syndications. He has held a number of Board and Board Advisory roles for private companies in the human resources, health and wellness, aged care, software, entertainment and finance sectors, including Director of a federal government licensed Innovation Investment Fund. In 2015 he acquired a corporate health division of an American multinational then grew it five-fold before selling it in 2021 to the subsidiary of a Canadian multinational. Mr. Meltzer is also a Director of the Australia-Israel Chamber of Commerce and Chairman of Independence Australia, a social enterprise. 

Ms Abby Macnish Niven was appointed as Chief Financial Officer for our Group in September 2024 and as Company Secretary in November 2024. Ms Macnish Niven is a Chartered Finance Analyst and holds Bachelor of Commerce and Bachelor of Science degrees from the University of Western Australia. She has extensive experience in private wealth management with groups including ANZ, UBS and Ord Minnett, and consults to a range of listed and unlisted companies in governance, finance and corporate structure.

There are no family relationships among our directors and senior executives.

Directors’ Interests

The relevant interest of each director, as defined by section 608 of the Corporations Act, in the share capital of the Group, as notified by the directors to the ASX in accordance with section 205G(1) of the Corporations Act, at the date of this report is as follows:

    Director           Number of            Number of     
                        ordinary           options over   
                         shares              ordinary     
                                              shares      
----------------------------------------------------------
Geoffrey Kempler          18,011,000            74,000,000
Lawrence Gozlan            4,545,455            58,515,152
Peter Marks                9